

## Figure 1

### A

DIQMTQSPST LSASVGDRVT ITC <u>SASSSVGYMH</u> WYQQKPG	40
CDR L1	
KAPKLLIY <u>DTSKLAS</u> GVPSR FSGSGSGTEF TLTISSLQPD	80
CDR L2	
DFATYYC <u>FQGSGYPFT</u> FGGGTKVEIK	106
CDR L3	

### B

QVTLRESGPA LVKPTQTLTL TCTFSGFSLs <u>TSGMSVG</u> WIR	40
CDR H1	
QPPGKALEWL A <u>DIWWDDKKDYNPSLKS</u> RLT ISKDTSKNQV	80
CDR H2	
VLKVTNMDPA DTATYYCAR <u>SMITNWFYFDV</u> W GQGTTVTVSS	120
CDR H3	

+

Affinity Comparison of Beneficial Com4 Clones




FIG. 2

+

### Figure 3

#### A

DIQMTQSPST LSASVGDRVT ITC <u>SASSSVGYMH</u> WYQQKPG	40
CDR L1	
KAPKLLIY <u>DTSKLAS</u> GVPSR FSGSGSGTEF TLTISSLQPD	80
CDR L2	
DFATYYC <u>FQGSFYPFT</u> FGGGTKVEIK	106
CDR L3	

#### B

QVTLRESGPA LVKPTQTLTL TCTFSGFSLs <u>TAGMSVG</u> WIR	40
CDR H1	
QPPGKALEWL A <u>DIWWDDKKDYNPSLKS</u> RLT ISKDTSKNQV	80
CDR H2	
VLKVTNMDPA DTATYYCAR <u>SMITNFYFDV</u> W GQGTTVTVSS	120
CDR H3	

## Figure 4

### A

DIQMTQSPST LSASVGDRVT ITC	<u>SASSSVGYMH</u>	WYQQKPG	40
	CDR L1		
KAPKLLIY	<u>DTFKLAS</u>	GVPSR FSGSGSGTEF	80
	CDR L2	TLTISSLQPD	
DFATYYC	<u>FQGSGYPFT</u>	FGGGTKVEIK	106
	CDR L3		

### B

QVTLRESGPA LVKPTQTLTL TCTFSGFSL	<u>TAGMSVG</u>	WIR	40
	CDR H1		
QPPGKALEWL A	<u>DIWWDDKKDYNPSLKS</u>	RLT ISKDTSKNQV	80
	CDR H2		
VLKVTNMDPA DTATYYCAR	<u>SMITNFYFDV</u>	W GQGTTVTVSS	120
	CDR H3		

## Figure 5

### A

DIQMTQSPST LSASVGDRVT ITC SASSSVGYMH WYQQKPG 40  
CDR L1

KAPKLLIY DTFKLAS GVPSR FSGSGSGTEF TLTISSLQPD 80  
CDR L2

DFATYYC FQGSFYPFT FGGGTKVEIK 106  
CDR L3

### B

QVTLRESGPA LVKPTQTLTL TCTFSGFSLs TPGMSVG WIR 40  
CDR H1

QPPGKALEWL A DIWWDDKKDYNPSLKS RLT ISKDTSKNQV 80  
CDR H2

VLKVTNMDPA DTATYYCAR SMITNFYFDV W GQGTTVTVSS 120  
CDR H3

## Figure 6

### A

DIQMTQSPST LSASVGDRVITC	<u>SASSSVGYMH</u>	WYQQKPG	40
	CDR L1		
KAPKLLIY	<u>DTFKLAS</u>	GVPSR FSGSGSGTEF	80
	CDR L2	TLTISSLQPD	
DFATYYC	<u>FQGSFYPT</u>	FGGGTKVEIK	106
	CDR L3		

### B

QVTLRESGPA LVKPTQTLTL TCTFSGFSL	<u>TAGMSVG</u>	WIR	40
	CDR H1		
QPPGKALEWL A	<u>DIWWDDKKDYNPSLKS</u>	RLT ISKDTSKNQV	80
	CDR H2		
VLKVTNMDPA DTATYYCAR	<u>SMITNFYFDV</u>	W GGGTTVTVSS	120
	CDR H3		

## Figure 7

### A

DIQMTQSPST LSASVGDRVITC <u>SASSSVGYMH</u> WYQQKPG	40
CDR L1	
KAPKLLIY <u>DTFKLAS</u> GVPSR FSGSGSGTEF TLTISSLQPD	80
CDR L2	
DFATYYC <u>FQGSYYPFT</u> FGGGTKVEIK	106
CDR L3	

### B

QVTLRESGPA LVKPTQTLTL TCTFSGFSL <u>TAGMSVG</u> WIR	40
CDR H1	
QPPGKALEWL A <u>DIWWDDKKDYNPSLKS</u> RLT ISKDTSKNQV	80
CDR H2	
VLKVTNMDPA DTATYYCAR <u>SMITNFYFDV</u> W GQGTTVTVSS	120
CDR H3	

**Figure 8**







Figure 9



Figur 10

RSV Microneutralization Assay with Fab comparing to Medi493

